Evidence map›Paper›PMID 38538059›Full record

Observational studyJournal of neurology, neurosurgery, and psychiatry2024

Epidemiology of myasthenia gravis in Denmark, Finland and Sweden: a population-based observational study.

John Vissing, Sari Atula, Mari Savolainen, Juha Mehtälä, Laila Mehkri, Tina Bech Olesen, Tero Ylisaukko-Oja, Ingrid Lindberg-Schager, Fredrik Berggren, Fredrik Piehl

Abstract readObservational Study
In one paragraph

Observational study in Journal of neurology, neurosurgery, and psychiatry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Disease severity as the dominant clinic-available marker of myasthenic crisis occurrence: a single-centre retrospective study.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026
    Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Observational
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

John VissingCopenhagen Neuromuscular Center, Department of Neurology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark john.vissing@regionh.dk.
Sari AtulaClinical Neurosciences, Neurology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Mari SavolainenUCB Pharma, Espoo, Finland.
Juha MehtäläMedEngine Oy, Helsinki, Finland.
Laila MehkriMedEngine DK ApS, Copenhagen, Denmark.
Tina Bech OlesenMedEngine DK ApS, Copenhagen, Denmark.ORCID 0000-0002-6295-7399
Tero Ylisaukko-OjaMedEngine Oy, Helsinki, Finland.
Ingrid Lindberg-SchagerUCB Pharma, Stockholm, Sweden.
Fredrik BerggrenUCB Pharma, Copenhagen, Denmark.
Fredrik PiehlDepartment of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.ORCID 0000-0001-8329-5219

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIncidence and prevalence rates of myasthenia gravis (MG) vary considerably across studies, and mortality risk is rarely addressed. We examined the prevalence and incidence rates, mortality and factors associated with mortality with MG.

methodThis was a registry linkage study based on nationwide health and administrative registries of Denmark, Finland and Sweden (populations of 5.9, 5.6 and 10.5 million, respectively). Patients with MG were identified based on International Classification of Diseases codes from inpatient and outpatient specialised care registries. Yearly prevalence, incidence and mortality rates in relation to the total background population were calculated from 2000 to 2020 (study period). The causes of death and factors associated with mortality were addressed separately.

resultsThe overall incidence of MG was 1.34 (95% CI 1.27 to 1.41), 1.68 (95% CI 1.60 to 1.75) and 1.62 (95% CI 1.56 to 1.68) per 100 000, and the overall prevalence per 100 000 was 18.56 (95% CI 18.31 to 18.81), 20.89 (95% CI 20.62 to 21.16) and 23.42 (95% CI 23.21 to 23.64) in Denmark, Finland and Sweden, respectively. The overall standardised mortality ratio (SMR) was 1.32 (95% CI 1.23 to 1.42) among patients with MG in Denmark, 1.23 (95% CI 1.15 to 1.33) in Finland, and 1.20 (95% CI 1.14 to 1.26) in Sweden, with higher SMR observed in women than men. Annual incidence and prevalence increased over time, whereas the SMR remained stable. The most common causes of death were MG, chronic ischaemic heart disease and acute myocardial infarction.

conclusionsThis population-based study from three Nordic countries highlights the need for improved care of patients with MG, especially young women.

Indexed as

Myasthenia GravisRegistriesAdolescentAdultAgedAged, 80 and overCause of DeathChildChild, PreschoolDenmarkFemaleFinlandHumansIncidenceMaleMiddle AgedCLINICAL NEUROLOGYEPIDEMIOLOGYMYASTHENIA

Identifiers

PMID38538059
PMCPMC11420710

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.